Ionis Pharmaceuticals IONS
Nasdaq · Pharmaceutical Preparations · $4.5BData provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
1 story has a settled next close so far (1 on the Wire). The record starts speaking at three.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via DatabentoOperating leverage — margins
| Line Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $810.5M | $587.4M | $787.6M | $705.1M | $943.7M | +33.8% | +3.9% | |
| Cost of Revenue (COGS) | $10.8M | $14.1M | $9.1M | $11.2M | $15.9M | +41.9% | +10.1% | |
| Research & Development (R&D) | $638.2M | — | $899.6M | $901.5M | $915.6M | +1.6% | +9.4% | |
| Selling, General & Admin (SG&A) | $186.3M | $150.3M | $232.6M | $267.5M | $393.9M | +47.3% | +20.6% | |
| Operating Income (EBIT) | $-30.2M | $-410.2M | $-353.7M | $-475.1M | $-381.7M | +19.7% | — | |
| Interest Expense | $9.3M | $8.1M | $12.7M | $17.0M | $17.3M | +1.6% | +16.6% | |
| Income Tax Expense | $-551,000 | $11.7M | $32.3M | $-6.2M | $1.8M | +128.9% | — | |
| GAAP Net Income | $-28.6M | $-269.7M | $-366.3M | $-453.9M | $-381.4M | +16.0% | — | |
| Diluted EPS | $-0.20 | $-1.90 | $-2.56 | $-3.04 | $-2.38 | +21.7% | — | |
| Diluted Shares | 141.0M | 141.8M | 143.2M | 149.5M | 160.0M | +7.0% | +3.2% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | $869.2M | $276.5M | $399.3M | $242.1M | $372.3M | +53.8% | −19.1% | |
| Inventory | $24.8M | $22.0M | $7.4M | $12.5M | $10.0M | −19.7% | −20.2% | |
| Total Current Assets | $2.3B | $2.2B | $2.6B | $2.6B | $3.0B | +14.1% | +6.3% | |
| Total Assets | $2.6B | $2.5B | $3.0B | $3.0B | $3.5B | +17.3% | +7.8% | |
| Total Current Liabilities | $240.6M | $311.6M | $448.1M | $309.3M | $781.6M | +152.7% | +34.3% | |
| Total Debt (Short + Long Term) | $2.2B | $1.2B | $1.3B | $1.3B | $2.2B | +79.1% | +0.0% | |
| Total Liabilities | $1.8B | $2.0B | $2.6B | $2.4B | $3.0B | +25.6% | +13.3% | |
| Stockholders' Equity | $771.7M | $572.9M | $386.7M | $588.4M | $489.1M | −16.9% | −10.8% | |
| Net Cash / (Net Debt) | $-1.4B | $-917.9M | $-909.3M | $-1.0B | $-1.9B | −85.2% | — | |
| Invested Capital | $2.1B | $1.5B | $1.3B | $1.6B | $2.4B | +47.6% | +2.4% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | $30.8M | $-274.4M | $-307.5M | $-500.9M | $-268.6M | +46.4% | — | |
| Depreciation & Amortization (D&A) | $15.5M | $14.3M | $10.3M | $9.6M | $10.0M | +4.1% | −10.3% | |
| Stock-Based Compensation (SBC) | $120.7M | $100.3M | $105.8M | $130.2M | $133.9M | +2.8% | +2.6% | |
| Capital Expenditures (CapEx) | $12.0M | $15.7M | $23.8M | $45.3M | $51.4M | +13.6% | +44.0% | |
| Free Cash Flow (FCF) | $18.8M | $-290.1M | $-331.3M | $-546.2M | $-320.0M | +41.4% | — | |
| True FCF (ex-SBC Owner Cash) | $-101.8M | $-390.4M | $-437.1M | $-676.4M | $-453.9M | +32.9% | — | |
| Share Repurchases (Buybacks) | $0 | $0 | — | — | $0 | — | — | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.